ReviewMedComm2026
Accelerate the Highly Efficient Development of mRNA Vaccines Through Advanced Computational Methods.
Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Beyond the genetic code: orchestrating epigenetic and immune landscapes with multivalent mRNA-exosome vaccines.Precision clinical medicine · 2026Review
- mRNA Therapeutics Beyond Infectious Diseases: Expanding Therapeutic Applications and Future Perspectives.Immunity, inflammation and disease · 2026Review
- Accelerate the Highly Efficient Development of mRNA Vaccines Through Advanced Computational Methods.MedComm · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
mRNA medicine is an emerging therapeutic approach that utilizes messenger RNA to synthesize functional proteins directly within target cells. This technology offers notable advantages including rapid development cycles, diverse therapeutic applications, and adaptable platform design for various diseases. However, mRNA therapeutic development faces substantial challenges, particularly in determining optimal mRNA sequences and developing effective delivery systems that ensure stability and achieve precise delivery. Current development processes often involve extensive experimental screening, highlighting the need for more efficient computational approaches. This review first introduces fundamental concepts in the mRNA vaccine field and systematically analyzes the roles and limitations of computational tools in advancing mRNA vaccine development across three key areas: sequence optimization, modification strategies, and delivery system optimization. Finally, we present the current application status of mRNA vaccines and discuss future prospects, highlighting emerging computational opportunities that may shape next-generation mRNA vaccine development. This review spans the entire mRNA vaccine development pipeline, providing a foundational resource for researchers and facilitating technological advancement in this rapidly evolving field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.